Advanced CSCC: What to Do When Surgery Just Isn’t Going to Cut It

Proprietary Educational Format:

Activity Overview

The goal of this activity is to provide education about immunotherapy in advanced CSCC that is not amenable to surgery or radiotherapy.

0.50 CE Credit(s)

Target Audience

This activity is intended for oncology, dermatology, and dermato-oncology clinicians who manage patients with cutaneous squamous cell carcinoma (CSCC). The goal of this activity is to provide education about immunotherapy in advanced CSCC that is not amenable to surgery or radiotherapy.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Effectively identify CSCC and assess risk of developing advanced disease
  • Delineate the safety and efficacy of immunotherapeutic agents for CSCC
  • Effectively manage immune-mediated adverse reactions associated with the mechanism of action of checkpoint inhibitors
  • Select therapy for individual patients according to current evidence and guidelines, offering clinical trial enrollment where appropriate

Activity Faculty

ModiB

Badri Modi, MD (Chair)

Assistant Clinical Professor  
Division of Dermatology
City of Hope
Duarte, California, United States

BranaI

Irene Brana, MD, PhD

Clinical Investigator, Molecular Therapeutic Research Unit and ENT Unit
Vall d’Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

MorenoV

Victor Moreno, MD, PhD

Director, Clinical Research Phase 1 Clinical Trial Unit
START Madrid-FJD
Hospital Fundación Jiménez Díaz
Madrid, Spain